Abstract: A kit for breeding a pig breed with resistance to the porcine transmissible gastroenteritis virus infection and application thereof. The systems includes a genetically edited protein, pAPN-sgRNA-1, pAPN-sgRNA-2, and a donor DNA. Effectively enzymatic cleavage can be made in two target sites of a pAPN gene by the gene editing protein. By replacing the fragment to be site-directed modified located between two target sites with donor DNA, a codon encoding tryptophan at position 737 in pAPN protein can be mutated to a codon encoding alanine, thereby achieving precise mutation of tryptophan to alanine at position 737 in a pAPN protein. The systems can avoid disruption or alteration of the normal expression of other amino acids in pAPN protein, therefore, the present invention maximally retains the physiological activity function of pAPN protein on the basis of resisting TGEV infection.
Abstract: The present invention provides a nucleic acid aptamer specifically recognizing ?-lactoglobulin and use thereof. The nucleic acid aptamer has a sequence as shown in SEQ ID NO:1, a sequence having 60% or higher homology to the sequence as shown in SEQ ID NO:1 and specifically recognizing ?-lactoglobulin, or a sequence derived from the sequence as shown in SEQ ID NO:1 and specifically recognizing ?-lactoglobulin. The nucleic acid aptamer specifically binds to the allergen ?-lactoglobulin in cow milk and dairy products, thereby providing a new tool for the high-sensitivity and low-cost detection of the allergen ?-lactoglobulin.
Type:
Grant
Filed:
June 24, 2020
Date of Patent:
November 26, 2024
Assignee:
JIANGNAN UNIVERSITY
Inventors:
Nuo Duan, Shijia Wu, Shuo Qi, Zhouping Wang
Abstract: Disclosed herein are novel variants of KCVN2 and their use, for example, in methods of treating a subject with a retinal disorder, such as CDSRR.
Type:
Grant
Filed:
May 19, 2022
Date of Patent:
October 15, 2024
Assignee:
Artema Therapeutics, Inc.
Inventors:
Shamil Sultanov, Maria Sultanova, Livia Carvalho, David Hunt, Rabab Rashwan, Pavel Y. Volchkov
Abstract: Functional human cortico-spinal-muscle assembled spheroids are generated by in vitro culture. Complete cortico-spinal-muscle spheroids (hCS-hSC-hSkM) are assembled from component cultured cell systems, where each cultured cell system is designed to provide specific sets of neural and/or muscle cells, and which components are functionally integrated in the assembled spheroid.
Type:
Grant
Filed:
June 20, 2019
Date of Patent:
October 8, 2024
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: A microfluidic system for separating biological entities includes a cooling device including a thermoelectric heat pump, a first fan, and a first heat exchanger disposed between the first fan and the thermoelectric heat pump; a first housing structure having a first shell that encases the first fan and the first heat exchanger; a microfluidic device and one or more piezoelectric transducers attached thereto; and a second housing structure reversibly attached to the first housing structure and having a second shell that encloses therein the microfluidic device and the one or more piezoelectric transducers. When the first and second housing structures are coupled, a first air passage is formed between a side of the first heat exchanger and an end of the microfluidic device, a second air passage is formed between the first fan and the piezoelectric transducers, thereby allowing air to circulate between the first and second air passages.
Abstract: The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells. Specifically described are methods to direct the lineage specific differentiation of hiPSC to sensitive neurons or neuronal fibers innervating the human skin, such as neural crest stem cells (NCPCs) and here called peripheral sensory neurons (PSNs) using novel culture conditions. It is also described a method for screening a biological agent in vitro. The PSNs obtained using the methods of the present invention are further contemplated for various uses including, but limited to, use in in vitro tests or disease modelling, such as drug discovery assays, cell therapy on a higher scale, detecting a range of skin irritants and other compounds of interest, for studying skin aging mechanism, and for producing a dermocosmetic product.